AOD-9604 Dosage Guide, Benefits & Side Effects

In the clinical trials that were conducted, AOD-9604 had a safety and tolerability profile similar to placebo overall, with mild-to-moderate headache being the most commonly reported adverse event at a rate comparable to placebo. Injection-site reactions (redness, swelling, itching) are the most frequently reported issue with subcutaneous use, and some users report transient mild nausea or bloating when starting. No participants in trials developed antibodies to the peptide, and no significant effects on glucose, insulin, or IGF-1 were observed. As with any unregulated research product, purity and dosing accuracy from a given supplier are not independently verified, which is itself a safety consideration.

Lyophilized (freeze-dried) AOD-9604 is typically reconstituted with bacteriostatic water, or a dilute (0.1-1%) acetic acid solution if it does not dissolve readily in plain water. The solvent is added gently against the vial wall (not directly onto the powder), and the vial is swirled or slowly rotated rather than shaken. Unreconstituted lyophilized powder should be kept refrigerated or frozen and protected from light. Once reconstituted, the solution is generally kept refrigerated at 2-8°C and used within about 2-4 weeks; for longer storage, some protocols recommend freezing single-use aliquots at -20°C.

AOD-9604 is not FDA-approved for any human use and cannot legally be compounded or sold as a drug for human administration in the United States (the FDA declined to add it to the 503A bulk substances list in December 2024). It is sold by suppliers labeled 'for research use only, not for human consumption,' which is the basis on which it is legally distributed. It is not classified as a scheduled controlled substance, but it is prohibited in professional sports under WADA anti-doping rules. Laws vary by country, and buyers are responsible for checking local regulations.

AOD-9604 and 'HGH Fragment 176-191' both refer to the same core amino acid sequence (residues 176-191 of human growth hormone) and are frequently used interchangeably in the peptide research community. AOD-9604 is technically a modified/stabilized version developed by Metabolic Pharmaceuticals with an added amino acid substitution for stability, but many vendors and users treat the two names as synonyms for the same fat-fragment peptide.